✦ LIBER ✦

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

✍ Scribed by Noboru Yamamoto; Tomohide Tamura; Nobuyuki Yamamoto; Kazuhiko Yamada; Yasuhide Yamada; Hiroshi Nokihara; Yutaka Fujiwara; Toshiaki Takahashi; Haruyasu Murakami; Narikazu Boku; Kentaro Yamazaki; Thomas A. Puchalski; Eisei Shin

Publisher: Springer
Year: 2009
Tongue: English
Weight: 436 KB
Volume: 64
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-009-0979-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I escalating single-dose and wee

A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors

✍ Kuniaki Shirao; Takayuki Yoshino; Narikazu Boku; Ken Kato; Tetsuya Hamaguchi; Hi 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 342 KB

A phase I dose escalation and pharmacoki

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

✍ E. Gabriela Chiorean; Srikar Malireddy; Anne E. Younger; David R. Jones; Mary-Ja 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 233 KB

A phase I dose escalation study of the p

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

✍ Edwina N. Scott; Anne L. Thomas; L. Rhoda Molife; Samreen Ahmed; Sarah Blagden; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 253 KB

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

A phase I study of the safety and pharma

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

✍ Herbert I. Hurwitz; Roger B. Cohen; J. Patrick McGovren; Samit Hirawat; William 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 308 KB

A phase I dose-escalation and bioavailab

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin

✍ M. Ranson; H. Shaw; J. Wolf; M. Hamilton; S. McCarthy; E. Dean; A. Reid; I. Juds 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 340 KB